Plain-English translation of NCT07105579 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Leukemia research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether blinatumomab—a medication that helps your immune system attack leukemia cells—combined with donor lymphocyte infusion (cells from your bone marrow donor) can prevent blood cancer from returning after you've had a stem cell transplant. The study focuses on people with a high-risk type of leukemia who are most likely to experience a relapse. Researchers want to see if this two-part approach is both safe and effective at keeping the cancer away.
Even after a successful stem cell transplant, some patients with high-risk leukemia have a very high chance—nearly 50% or higher—that the cancer will come back, which significantly shortens survival. This trial exists to find out whether giving this medication as a preventive treatment after transplant can reduce that relapse risk and help more patients stay cancer-free.
You likely qualify if…
You likely don't qualify if…
You would receive blinatumomab infusions combined with donor lymphocyte infusions as maintenance therapy after your stem cell transplant. The study takes place at multiple medical centers and involves regular clinic visits for treatment administration, blood tests, and monitoring of your health and response to the medication. The exact schedule and duration will be explained to you by the research team, and you would be monitored closely for both how well the treatment works and any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China